Insulin resistance (IR) is a frequent multifactorial complication of uremia. It is considered an independent predictor for cardiovascular events and mortality in patients with chronic kidney disease (CKD); it may be an important therapeutic target in management of CKD. The study was conducted to evaluate the effect of short-term treatment with recombinant human erythropoietin (rHuEpo) therapy on IR, in diabetic and non-diabetic end stage renal disease (ESRD) patients on hemodialysis.
(2021). Effect of Short-Term Erythropoietin Therapy on Insulin Resistance in Diabetic and Non-Diabetic Hemodialysis Patients. Egyptian Society of Diabetes and Lipidology Journal, 1(1), -. doi: 10.21608/esdlj.2021.455579
MLA
. "Effect of Short-Term Erythropoietin Therapy on Insulin Resistance in Diabetic and Non-Diabetic Hemodialysis Patients", Egyptian Society of Diabetes and Lipidology Journal, 1, 1, 2021, -. doi: 10.21608/esdlj.2021.455579
HARVARD
(2021). 'Effect of Short-Term Erythropoietin Therapy on Insulin Resistance in Diabetic and Non-Diabetic Hemodialysis Patients', Egyptian Society of Diabetes and Lipidology Journal, 1(1), pp. -. doi: 10.21608/esdlj.2021.455579
VANCOUVER
Effect of Short-Term Erythropoietin Therapy on Insulin Resistance in Diabetic and Non-Diabetic Hemodialysis Patients. Egyptian Society of Diabetes and Lipidology Journal, 2021; 1(1): -. doi: 10.21608/esdlj.2021.455579
)
